What is Relief Therapeutics Holding AG?
MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology.
RLFTY · Verdict
Solid reward · elevated risk
RLFTY stands out on valuation and volatility, but watch the cash flow signal.
Based on 88% data coverage
RLFTY · Verdict
P/E 1.2×
Above average
-37% free-cash-flow margin
-203% net margin · -42% ROE
Model-based scoring. For information only — not financial advice.
MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 145.58M.
The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.